CN108578653A - Preparation process for the pharmaceutical preparation for treating bronchitis - Google Patents
Preparation process for the pharmaceutical preparation for treating bronchitis Download PDFInfo
- Publication number
- CN108578653A CN108578653A CN201810291264.5A CN201810291264A CN108578653A CN 108578653 A CN108578653 A CN 108578653A CN 201810291264 A CN201810291264 A CN 201810291264A CN 108578653 A CN108578653 A CN 108578653A
- Authority
- CN
- China
- Prior art keywords
- preparation process
- extracting solution
- alcohol
- process according
- stirs evenly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 206010006451 bronchitis Diseases 0.000 title claims abstract description 14
- 239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000003814 drug Substances 0.000 claims abstract description 25
- 238000003756 stirring Methods 0.000 claims abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 238000010008 shearing Methods 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 238000004821 distillation Methods 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims description 21
- 235000019441 ethanol Nutrition 0.000 claims description 21
- 239000000843 powder Substances 0.000 claims description 16
- 235000004347 Perilla Nutrition 0.000 claims description 13
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 241000471262 Ardisia japonica Species 0.000 claims description 6
- 241000758794 Asarum Species 0.000 claims description 6
- 241001465251 Ephedra sinica Species 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- 244000223014 Syzygium aromaticum Species 0.000 claims description 6
- 235000016639 Syzygium aromaticum Nutrition 0.000 claims description 6
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 235000008397 ginger Nutrition 0.000 claims description 6
- 235000019508 mustard seed Nutrition 0.000 claims description 6
- 239000004745 nonwoven fabric Substances 0.000 claims description 6
- 239000000341 volatile oil Substances 0.000 claims description 5
- 238000002386 leaching Methods 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims description 3
- 229920001131 Pulp (paper) Polymers 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 238000009413 insulation Methods 0.000 claims description 3
- 238000007759 kiss coating Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 3
- 239000004033 plastic Substances 0.000 claims description 2
- 238000007789 sealing Methods 0.000 claims description 2
- 244000124853 Perilla frutescens Species 0.000 claims 2
- 244000273928 Zingiber officinale Species 0.000 claims 2
- 238000000605 extraction Methods 0.000 claims 1
- 238000005516 engineering process Methods 0.000 abstract description 7
- 230000000857 drug effect Effects 0.000 abstract description 3
- 238000009472 formulation Methods 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 19
- 241000700159 Rattus Species 0.000 description 13
- 208000006673 asthma Diseases 0.000 description 12
- 241000229722 Perilla <angiosperm> Species 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 230000005284 excitation Effects 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 4
- 206010013975 Dyspnoeas Diseases 0.000 description 4
- 108090000176 Interleukin-13 Proteins 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 206010070834 Sensitisation Diseases 0.000 description 4
- 241000234314 Zingiber Species 0.000 description 4
- 238000000889 atomisation Methods 0.000 description 4
- 208000000059 Dyspnea Diseases 0.000 description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 206010044302 Tracheitis Diseases 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000588748 Klebsiella Species 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 208000023819 chronic asthma Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 239000013010 irrigating solution Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 208000036065 Airway Remodeling Diseases 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 206010031123 Orthopnoea Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- 230000001408 fungistatic effect Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000001709 ictal effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000012144 orthopnea Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/17—Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/26—Aristolochiaceae (Birthwort family), e.g. heartleaf
- A61K36/268—Asarum (wild ginger)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to field of medicine preparing technology, the preparation process of the pharmaceutical preparation for treating bronchitis is disclosed comprising following steps：Step 1）Weigh raw material, step 2）Shearing, distillation, step 3）Alcohol extracting, step 4）Water carries, step 5）It stirs evenly, dry, step 6）Prepare patch.The present invention improves known formulations, improves drug effect.
Description
Technical field
The invention belongs to field of medicine preparing technology, and in particular, to the system of the pharmaceutical preparation for treating bronchitis
Standby technique.
Background technology
Bronchitis refers to the chronic nonspecific inflammation of trachea-bronchial epithelial cell mucous membrane and its surrounding tissue.Bronchitis master
It is that the repeated infection of virus and bacterium forms bronchial chronic nonspecific inflammation to want reason.When mercury dropped, respiratory tract
Small blood vessel spasm ischemic, defense function decline etc. are conducive to cause a disease；The chronic stimulations such as smog dust, pollution air can also fall ill；It inhales
Cigarette makes bronchial spasm, mucous membrane variation, ciliary movement reduction, mucilage secretion increase advantageous infectivity；Intolerance factors also have certain pass
System.Clinical manifestation often adds at night and early morning breaking-out for ictal expiratory dyspnea and with wheezing sound, cough and expectoration
It is acute.Bronchitis such as diagnosis and treatment not in time, air flue irreversibility constriction and Airway Remodeling, severe patient's quilt can be generated with the extension of the course of disease
Compel to take seat or be in orthopnea, dry cough or a large amount of white foam phlegm of cough, or even cyanosis occur etc..Some teenagers roar
Asthma shape shows as occurring uncomfortable in chest, cough and expiratory dyspnea when movement, is common clinical.Clinical treatment is mainly applied at present
The methods of hormone controls, not only costly, and easily recurrence, and greatly economic and mental burden is brought to patient.
Fragrant fiber crops cold asthma patch is existing market drug on sale, can be used to treat the symptoms such as infant bronchitis, asthma, have
Good effect, less toxic side effect and other advantages, corresponding patent are also on the books；The effect of drug, is also to be hoisted, and applicant is to this
Drug has carried out continuous improvement, to promote its curative effect.Wherein, patented technology " CN2013103914698, a kind of fragrant numb cold asthma
Patch and its preparation process " and " CN2015101716371, a kind of application that fragrant numb cold asthma is pasted and its detection method " are to existing skill
The improvement of art, mainly by adding plurality of raw materials medicine, effect is better than known drug, more but there are raw material types, and pharmacology is made
With it is indefinite and of high cost the defects of；Patented technology " CN2017109499108 " to the technique of existing fragrant numb cold asthma patch into
Improvement is gone, drug effect caused by avoiding distillation time too long and leading to the destruction of bitter glycosides, general flavone and total phenol acid content is lost；
On the basis of the patented technology, applicant continues to improve patch.
Invention content
On the basis of existing technology, the present invention is improved, and provides the pharmaceutical preparation for treating bronchitis
Preparation process.
The present invention is achieved by the following technical solution：
Preparation process for the pharmaceutical preparation for treating bronchitis comprising following steps：Step 1）Weigh raw material, step 2）
Shearing, distillation, step 3）Alcohol extracting, step 4）Water carries, step 5）It stirs evenly, dry, step 6）Prepare patch.
Further, the step 1）Raw material is weighed, including：Weigh cloves 30g, asarum 100g, ginger 200g, perilla leaf
170g, Chinese ephedra 200g, mustard seed 200g, ardisia japonica 300g.
Further, the step 2）Shearing, distillation, including：Cloves and asarum are mixed, crushes, sieves with 100 mesh sieve,
Ginger is sliced, and above-mentioned raw materials are mixed, and then adds the water of 6 times of weight, and soak is obtained with high-speed shearing machine shearing 30min,
Shearing rotating speed is 2000rpm, is then distilled 2 hours, volatile oil is separately set, and extracting solution A and the dregs of a decoction are spare.
Further, the step 3）Alcohol extracting, including：Perilla leaf is taken, is crushed, 200 mesh sieve is crossed, is placed in reaction kettle, so
Three times, each 6h is then combined with leaching liquor three times to 85% alcohol steep of 5 times of weight of addition, is concentrated under reduced pressure into no alcohol, obtains afterwards
To extracting solution B.
Further, the step 4）Water carries, including：Chinese ephedra, mustard seed and ardisia japonica are mixed, 200 purposes are ground into
Powder is then added in reaction kettle, then adds the water of 5 times of weight, is stirred evenly, and is heated to 70 DEG C, and is controlled pressure and be
1Mpa, heat-insulation pressure keeping 30min, is then down to normal pressure and temperature, and extracting solution C is collected by filtration, and filter residue is spare.
Further, the step 5）It stirs evenly, dry, including：By step 4）Gained filter residue and with step 1）The gained dregs of a decoction
Merge, adds the water of 6 times of weight to decoct 1 hour, extracting solution D is collected in filtration；Merge extracting solution A, extracting solution B, extracting solution C and carries
Liquid D is taken, the clear cream that density is 1.20g/ml is concentrated into, adds ethyl alcohol to make alcohol content up to 50%, stir evenly, stand 24 hours；Take supernatant
Ethyl alcohol is recovered under reduced pressure in liquid, is concentrated into the thick paste that density is 1.28g/ml, then vacuum freeze drying, sieves with 100 mesh sieve to obtain drug
Dry powder.
Further, the step 6）Patch is prepared, including：Dry powder drug is taken, suitable Medical PSA is added,
It stirs evenly, addition accounts for the isopropanol of dry powder drug 5wt%, the azone of 2wt% and step 2）Gained volatile oil stirs evenly, and applies
It is distributed in non-woven fabrics, is dried, cutting is placed on kiss-coating mesh non-woven fabrics, and surrounding adds paper pulp guard ring, separate paper is covered, with plastic-aluminum
Package encapsulation to get.
Compared with prior art, beneficial effects of the present invention include but is not limited to mainly the following aspects：
Perilla leaf uses easy alcohol steep technique, more simple and feasible, and a large amount of flavonoids and lactone are contained in extract
Substance has the function of stronger anti-oxidant and inhibits inflammation；By adding the alcohol extract of perilla leaf, drug effect is improved, is better than
Product and technique known in the art, has preferable application prospect, can carry out the clinical research of next step.The medicine of the present invention
In object preparation, each drug extract component is an organic whole, indispensable, lacks perilla leaf extract, then drug is whole
Body reduces antibacterial and anti-inflammatory treatment significant effect, can further be verified in the clinical test of next step.
Specific implementation mode
In order to make those skilled in the art better understand the technical solutions in the application, having below in conjunction with the application
Body embodiment more clearly and completely describes the present invention, it is clear that described embodiment is only the application one
Divide embodiment, instead of all the embodiments.Based on the embodiment in the application, those of ordinary skill in the art are not making
The every other embodiment obtained under the premise of creative work, should all belong to the scope of protection of the invention.
Embodiment 1
Preparation process for the pharmaceutical preparation for treating bronchitis comprising following steps：
Step 1）Weigh cloves 30g, asarum 100g, ginger 200g, perilla leaf 170g, Chinese ephedra 200g, mustard seed 200g, ardisia japonica
300g；
Step 2）Cloves and asarum are mixed, crushes, sieves with 100 mesh sieve, above-mentioned raw materials are mixed, then add 6 by ginger slice
The water of times weight obtains soak with high-speed shearing machine shearing 30min, then shearing rotating speed 2000rpm is distilled 2 hours, waved
Hair oil is separately set, and extracting solution A and the dregs of a decoction are spare；
Step 3）Perilla leaf is taken, is crushed, 200 mesh sieve is crossed, is placed in reaction kettle, then add 85% alcohol steep of 5 times of weight
Three times, each 6h is then combined with leaching liquor three times, is concentrated under reduced pressure into no alcohol, obtains extracting solution B；
Step 4）Chinese ephedra, mustard seed and ardisia japonica are mixed, 200 mesh powders is ground into, is then added in reaction kettle, then add
The water for adding 5 times of weight, stirs evenly, and is heated to 70 DEG C, and it is 1Mpa, heat-insulation pressure keeping 30min to control pressure, is then down to often
Normal pressure and temperature, is collected by filtration extracting solution C, and filter residue is spare；
Step 5）By step 4）Gained filter residue and with step 1）The gained dregs of a decoction merge, and add the water of 6 times of weight to decoct 1 hour, filtration
Collect extracting solution D；Merge extracting solution A, extracting solution B, extracting solution C and extracting solution D, it is the clear of 1.20g/ml to be concentrated into density
Cream adds ethyl alcohol to make alcohol content up to 50%, stirs evenly, and stands 24 hours；Supernatant is taken, ethyl alcohol is recovered under reduced pressure, being concentrated into density is
The thick paste of 1.28g/ml, then vacuum freeze drying, sieves with 100 mesh sieve to obtain dry powder drug；
Step 7）Dry powder drug is taken, suitable Medical PSA is added（Dosage is 10mg/cm2）, stir evenly, addition accounts for
The isopropanol of dry powder drug 5wt%, the azone of 2wt% and step 2）Gained volatile oil stirs evenly, and is coated on non-woven fabrics, dries
Dry, cutting is placed on kiss-coating mesh non-woven fabrics, and surrounding adds paper pulp guard ring, covers separate paper, with aluminum-plastic packaged sealing to get.
Usage：External application is affixed on bilateral fei shu, Dingchuan and Gaomang point.Per the patch of cave one time one, once a day, patch 6 is small every time
When.Rule：4cm×4cm；Storage：It is closed, it sets at shady and cool drying.
Comparative example 1
Perilla leaf is not added, remaining is the same as embodiment 1.
Embodiment 2
Animal toxicity test：Patch prepared by embodiment 1 is affixed on de- plucked rabbit back (double lung projections back), is pasted every time
6 hours, daily patch 1 time, continuous 2 weeks.To its blood picture, lung, Liver and kidney function observation, toxic effect is found no；Through pathological section
The toxic damage of the organs such as the heart, liver, spleen, lung, kidney is not found.Therefore the clinical recommended drug dosage of prompt is safe to use.
Embodiment 3
In vitro Bactericidal Experiments：
The dry powder drug of dry powder drug and comparative example 1 prepared by embodiment 1 is dissolved in water respectively, adds sterilizing MH cultures
Base, mixing postcooling are spare so that in culture medium the ultimate density of drug be 160,80,40,20,10,5,2.5,1.25,
0.625、0.313(mg/ml)；Set blank control group simultaneously.The common pathogen staphylococcus aureus of bronchitis, tracheitis
Klebsiella and Pseudomonas aeruginosa are observed in 37 DEG C of constant temperature incubations as test organisms as a result, and recording MIC for 24 hours50(mg/ml) value,
The results are shown in Table 1.
Table 1
| Pathogenic bacteria | Embodiment 1 | Comparative example 1 |
| Staphylococcus aureus | 22 | 29 |
| Tracheitis klebsiella | 13 | 16 |
| Pseudomonas aeruginosa | 8 | 12 |
Conclusion：As can be seen from Table 1, the dry powder drug of the use of the embodiment of the present invention 1 is to staphylococcus aureus, tracheitis gram
The pathogenic bacteria of a variety of bronchitis such as the primary bacterium of thunder and Pseudomonas aeruginosa all have to be acted on compared with high inhibition, the difference compared with comparative example 1
Significantly, each drug extract component of the prompt present invention is an organic whole, indispensable, reduces perilla leaf extract, then
Whole fungistatic effect significantly reduces.
Embodiment 4
Zoopery
Experimental animal selects SPF grades of Male Wistar Rats 80, our company's Experimental Animal Center to provide, 6 week old, weight（175
±20）G is used after raising 1 week in 30% environment of room epidemic disaster；Be randomly divided into 4 groups, respectively normal group, asthmatic model group,
1 group of embodiment, 1 group of comparative example, every group 20.
Chronic asthma rat model is established in addition to normal group, remaining each group rat prepares egg protein with reference to Palmans methods
（OVA）Sensitization chronic asthma airway inflammation rat model.Received for the first time from the 1st day OVA be injected to the 14th day be sensitisation phase,
15th day to the 56th day is lasting excitation phase（6 weeks）.Sensitisation phase：It gives within 1st day rats by intraperitoneal injection OVA and aluminium hydroxide is mixed
Close solution 1mL（Containing OVA10mg, aluminium hydroxide 100mg）；It is injected intraperitoneally again within 8th day and reinforces sensitization.Excitation phase：15th day
Start, rat is put in and is provided for oneself in closed atomization box, give 1%OVA solution atomizations sucking, each 30min, the next day 1 time, therebetween
The reactions such as rat sneeze, breathing, lip, abdomen and mobility are observed, until atomization in the 56th day terminates.
Normal rats activity is normal, the performances such as no syndrome characterized by dyspnea, remaining each group rat shows as hair dimness, perpendicular hair, burnout.
There is typical asthma sample breaking-out in partial rat when atomization excitation, is such as short of breath, pants, breathing of nodding, abdomen opens and close, action subtracts
It is few, and gradually aggravated as excitation number increases symptom.There is paroxysmal sneeze in partial rat, as excitation number increases sneeze
Number increases.
GP TH carries out respective handling from the 57th day to each group rat.Normal group, asthmatic model group：Normal feed is not done
Other processing；1 group of embodiment, comparative example 1：It is pasted on bilateral fei shu, Pishu, Shen Shu point, in immobilization with adhesive tape to acupuncture point, after 6h
Removal, one time a day, treats 14d altogether.
10% chloraldurate of index observing and detection method（3.5mL/kg）Intraperitoneal injection of anesthesia.After rat anesthesia, disinfection
Skin opens thoracic cavity, and folder closes its right principal bronchus, from the tracheae slowly left lung of saline injection 4mL lavations, 3 times repeatedly, from
The heart takes its supernatant and is dispensed.Index observing：Normal rats alveolar form rule, a small amount of inflammatory cell leaching of interstitial lung
Profit；Model group rats alveolar space reduces, and inside sees that inflammatory cell infiltration and mucus bolt, interstitial lung thicken；Above-mentioned observation result carries
Show modeling success.IL-4, IL-6, IL-13 content in ELISA method detection BAL fluid（pg/ml）.Concrete outcome
It is shown in Table 2：
Table 2
| Group | IL-4 | IL-6 | IL-13 |
| Normal group | 1.65±0.31 | 21.59±4.35 | 24.98±5.41 |
| Asthmatic model group | 4.47±0.48 | 26.97±6.78 | 33.26±7.16 |
| 1 group of embodiment | 1.83±0.40 | 23.46±3.47 | 26.89±6.13 |
| 1 group of comparative example | 2.07±0.45 | 24.91±5.32 | 28.77±5.46 |
Conclusion：As shown in upper table 2, compared with normal group, IL-4, IL-6, IL-13 content are apparent in asthmatic model group irrigating solution
It increases, in conjunction with observation index, prompts modeling success.Compared with asthmatic model group, 1 group of 1 group of embodiment, comparative example rat irrigating solution
Middle IL-4, IL-6, IL-13 content is substantially reduced, and illustrates that level of inflammation is substantially reduced；Wherein, 1 group of embodiment is added to properly
The perilla leaf extract of amount, the effect that inflammation inhibits are better than 1 group of comparative example, it is seen then that add purple perilla on the basis of known formulations
Leaf extract can improve therapeutic effect, can further be verified in follow-up clinical experiment.
Although above having used general explanation, specific implementation mode and clinical test, the present invention is made to retouch in detail
It states, but on the basis of the present invention, it can be made some modifications or improvements, this is apparent to those skilled in the art
's.Therefore, modifications or improvements on the basis of without departing from initiative spirit of the present invention, belong to claimed
Range.
Claims (7)
1. the preparation process of the pharmaceutical preparation for treating bronchitis comprising following steps：Step 1）Weigh raw material, step
2）Shearing, distillation, step 3）Alcohol extracting, step 4）Water carries, step 5）It stirs evenly, dry, step 6）Prepare patch.
2. preparation process according to claim 1, which is characterized in that the step 1）Raw material is weighed, including：Weigh cloves
30g, asarum 100g, ginger 200g, perilla leaf 170g, Chinese ephedra 200g, mustard seed 200g, ardisia japonica 300g.
3. preparation process according to claim 2, which is characterized in that the step 2）Shearing, distillation, including：By cloves
And asarum mixing, it crushes, sieves with 100 mesh sieve, above-mentioned raw materials are mixed, the water of 6 times of weight then added, with height by ginger slice
Fast cutter shearing 30min obtains soak, and then shearing rotating speed 2000rpm distills 2 hours, volatile oil is separately set, extracting solution
A and the dregs of a decoction are spare.
4. preparation process according to claim 3, which is characterized in that the step 3）Alcohol extracting, including：Take perilla leaf, powder
It is broken, 200 mesh sieve is crossed, is placed in reaction kettle, then three times, each 6h is then combined with 85% alcohol steep of 5 times of weight of addition
Leaching liquor three times is concentrated under reduced pressure into no alcohol, obtains extracting solution B.
5. preparation process according to claim 4, which is characterized in that the step 4）Water carries, including：By Chinese ephedra, mustard seed
And ardisia japonica mixing, 200 mesh powders are ground into, are then added in reaction kettle, then add the water of 5 times of weight, stirring is equal
It is even, 70 DEG C are heated to, and it is 1Mpa to control pressure, then heat-insulation pressure keeping 30min is down to normal pressure and temperature, extraction is collected by filtration
Liquid C, filter residue are spare.
6. preparation process according to claim 5, which is characterized in that the step 5）It stirs evenly, dry, including：By step
4）Gained filter residue and with step 1）The gained dregs of a decoction merge, and add the water of 6 times of weight to decoct 1 hour, extracting solution D is collected in filtration；Merge
Extracting solution A, extracting solution B, extracting solution C and extracting solution D are concentrated into the clear cream that density is 1.20g/ml, ethyl alcohol are added to make alcohol content
It up to 50%, stirs evenly, stands 24 hours；Supernatant is taken, ethyl alcohol is recovered under reduced pressure, is concentrated into the thick paste that density is 1.28g/ml, then
Vacuum freeze drying sieves with 100 mesh sieve to obtain dry powder drug.
7. preparation process according to claim 6, which is characterized in that the step 6）Patch is prepared, including：Take drug dry
Powder is added suitable Medical PSA, stirs evenly, be added account for the isopropanol of dry powder drug 5wt%, 2wt% azone with
And step 2）Gained volatile oil stirs evenly, and is coated on non-woven fabrics, dries, and cutting is placed on kiss-coating mesh non-woven fabrics, surrounding adds
Paper pulp guard ring, cover separate paper, with it is aluminum-plastic packaged sealing to get.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810291264.5A CN108578653A (en) | 2018-04-03 | 2018-04-03 | Preparation process for the pharmaceutical preparation for treating bronchitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810291264.5A CN108578653A (en) | 2018-04-03 | 2018-04-03 | Preparation process for the pharmaceutical preparation for treating bronchitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108578653A true CN108578653A (en) | 2018-09-28 |
Family
ID=63625253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810291264.5A Pending CN108578653A (en) | 2018-04-03 | 2018-04-03 | Preparation process for the pharmaceutical preparation for treating bronchitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108578653A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1176115A (en) * | 1996-09-06 | 1998-03-18 | 刘贵云 | Asthma curing plaster |
| CN107670005A (en) * | 2017-10-13 | 2018-02-09 | 翔宇药业股份有限公司 | The preparation technology and its detection method of the fragrant cold asthma patch of fiber crops |
| CN107670004A (en) * | 2017-10-13 | 2018-02-09 | 翔宇药业股份有限公司 | A kind of pharmaceutical preparation for being used for asthma, bronchitis and preparation method thereof |
-
2018
- 2018-04-03 CN CN201810291264.5A patent/CN108578653A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1176115A (en) * | 1996-09-06 | 1998-03-18 | 刘贵云 | Asthma curing plaster |
| CN107670005A (en) * | 2017-10-13 | 2018-02-09 | 翔宇药业股份有限公司 | The preparation technology and its detection method of the fragrant cold asthma patch of fiber crops |
| CN107670004A (en) * | 2017-10-13 | 2018-02-09 | 翔宇药业股份有限公司 | A kind of pharmaceutical preparation for being used for asthma, bronchitis and preparation method thereof |
Non-Patent Citations (4)
| Title |
|---|
| 刘贵云等: "治喘伏贴灵治疗小儿哮喘139例疗效观察", 《中医杂志》 * |
| 宋永刚著: "《神农本草经讲读》", 29 February 2012, 中国中医药出版社 * |
| 汪毅主编: "《黔本草.第1卷》", 31 March 2015, 贵州科技出版社 * |
| 陈光主编: "《足浴良方1000则》", 30 April 2016, 金盾出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101626437B1 (en) | Cosmetic composition for improving skin inflammation or reducing skin irritation | |
| CN107670004A (en) | A kind of pharmaceutical preparation for being used for asthma, bronchitis and preparation method thereof | |
| CN106109367A (en) | A kind of toothpaste with antibacterial action containing bamboo leaf flavone and preparation method thereof | |
| CN102875513A (en) | Microcrystal catechin and preparation method thereof | |
| JP2010106024A (en) | Pharmaceutical composition for treating and preventing cancer, and health-functional food for improving and preventing cancer containing the same | |
| KR101930264B1 (en) | Cosmetic composition for inhibiting secretion of sebum and for improving acne symptoms containing natural complex extract | |
| CN102218026B (en) | Use of willow leaf wintersweet extract in preparation of mosquito repelling agent | |
| KR101816821B1 (en) | Functioanl tea with anticancer activity and manufacturing method thefeof | |
| JP6715007B2 (en) | Natural benzaldehyde water production method, natural benzaldehyde water produced by the production method, and antitumor agent containing the natural benzaldehyde water | |
| CN108578653A (en) | Preparation process for the pharmaceutical preparation for treating bronchitis | |
| CN108523121A (en) | A kind of functional food and preparation method thereof of anti-haze clearing lung-heat | |
| KR20140054951A (en) | Whitening cosmetic composition containing mixture of fermented herbal extracts | |
| CN108310342A (en) | A kind of pharmaceutical preparation for treating bronchitis | |
| JP2011510912A (en) | Lacanka extract-containing wound healing agent | |
| CN108524331A (en) | A kind of Chinese yew solid perfume and preparation method thereof | |
| CN107670005A (en) | The preparation technology and its detection method of the fragrant cold asthma patch of fiber crops | |
| TWI811478B (en) | Preparation method and pharmaceutical composition for the extract and composition of antrodia cinnamomea. | |
| TW200948272A (en) | Medium for long-dan tissue culture and extract thereof for supporting liver function and method for making the same | |
| JP2018083794A (en) | Epithelial cell activator | |
| JP2020023583A (en) | Agent containing lignin extract as active ingredient | |
| CN104306764B (en) | A kind of Chinese medicine compound prescription spray for being used to control rhinitis | |
| JP4979053B2 (en) | Anticancer agent containing gentian extract, health supplement and medicinal cosmetic, and method for producing gentian extract | |
| CN115212247B (en) | Preparation of nitraria tangutorum bobr and application thereof | |
| CN110251629A (en) | A kind of Chinese traditional medicine composition and its application for treating asthma | |
| CN108339104A (en) | Patch for bronchial asthma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180928 |
|
| WD01 | Invention patent application deemed withdrawn after publication |